Integrating Image-Based High-Content Screening with Mouse Models Identifies 5-Hydroxydecanoate as a Neuroprotective Drug for Paclitaxel-Induced Neuropathy

Chemotherapy-induced neurotoxicity is a common adverse effect of cancer treatment. No medication has been shown to be effective in the prevention or treatment of chemotherapy-induced neurotoxicity. This study aimed to discover potential neuroprotective drugs for paclitaxel-induced neurotoxicity. An image-based high-content platform was first developed to screen for potential neuroprotective drugs. The screening system comprised of automated image acquisition and multiparameter analysis, including neuronal viability, neurite outgrowth, and synaptogenesis. By this platform, we obtained a candidate list from compound libraries. In the drug screening from compound libraries of ion channel ligands, REDOX and GABAergic ligands, 5-hydroxydecanoate (5-HD) exhibited the most significant neuroprotective effects against paclitaxel-induced neurotoxicity in both cortical and dorsal root ganglion (DRG) neurons. In mouse behavioral tests, 5-HD restored the thermal sensitivity and alleviated mechanical allodynia induced by paclitaxel. Electron micrographs of sciatic nerve revealed that 5-HD reduced the damages caused by paclitaxel in the nonmyelinated and smaller myelinated fibers. The mechanistic study on DRG neurons suggested that 5-HD rescued the dysregulation of intracellular calcium homeostasis provoked by paclitaxel. Importantly, 5-HD did not jeopardize the antitumor effect of paclitaxel in tumor xenograft models. In conclusion, we established an imaged-based high-content screening platform and a protocol for verifying the neuroprotective effect in vivo, by which 5-HD was identified and validated as a potential neuroprotective drug for paclitaxel-induced neuropathy. Mol Cancer Ther; 14(10); 2206–14. ©2015 AACR.

[1]  J. Arezzo,et al.  Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. , 2008, Clinical advances in hematology & oncology : H&O.

[2]  Timothy J Shafer,et al.  Assessment of chemical effects on neurite outgrowth in PC12 cells using high content screening. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  B. Ehrlich,et al.  Prevention of paclitaxel‐induced peripheral neuropathy by lithium pretreatment , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  M. Koltzenburg,et al.  Peripheral nerve damage associated with administration of taxanes in patients with cancer. , 2008, Critical reviews in oncology/hematology.

[5]  Alison M. Thomas,et al.  The role of ATP‐sensitive potassium channels in cellular function and protection in the cardiovascular system , 2014, British journal of pharmacology.

[6]  Chengshui Chen,et al.  Potential therapeutic targets for hypoxia-induced pulmonary artery hypertension , 2014, Journal of Translational Medicine.

[7]  S. Swain,et al.  Peripheral neuropathy induced by microtubule-stabilizing agents. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Harrill,et al.  Use of high content image analysis to detect chemical-induced changes in synaptogenesis in vitro. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[9]  A. Panov,et al.  Fatty Acids in Energy Metabolism of the Central Nervous System , 2014, BioMed research international.

[10]  A. Windebank,et al.  Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. , 2012, Neuro-oncology.

[11]  A. Hohmann,et al.  A Lipid Gate for the Peripheral Control of Pain , 2014, The Journal of Neuroscience.

[12]  P. Baas,et al.  Identification of a Microtubule-associated Motor Protein Essential for Dendritic Differentiation , 1997, The Journal of cell biology.

[13]  Hsien-Chang Chang,et al.  Calcium store sensor stromal-interaction molecule 1-dependent signaling plays an important role in cervical cancer growth, migration, and angiogenesis , 2011, Proceedings of the National Academy of Sciences.

[14]  I. Utsunomiya,et al.  Effect of paclitaxel on transient receptor potential vanilloid 1 in rat dorsal root ganglion , 2013, PAIN®.

[15]  A. McPhail,et al.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. , 1971, Journal of the American Chemical Society.

[16]  G. Bennett,et al.  Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin , 2012, PAIN.

[17]  P. Séguéla,et al.  Contribution of TRPC3 to store-operated calcium entry and inflammatory transductions in primary nociceptors , 2014, Molecular pain.

[18]  G. Y. Wong,et al.  Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells , 2007, Experimental Neurology.

[19]  A. Sparreboom,et al.  Comparative in vitro properties and clinical pharmacokinetics of paclitaxel following the administration of Taxol® and Paxene® , 2005, Cancer biology & therapy.

[20]  L. Saha,et al.  Evaluation of Lercanidipine in Paclitaxel-Induced Neuropathic Pain Model in Rat: A Preliminary Study , 2012, Pain research and treatment.

[21]  G. Banker,et al.  Immunocytochemical localization of tubulin and microtubule-associated protein 2 during the development of hippocampal neurons in culture , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  Thomas Hartung,et al.  Workgroup Report: Incorporating In Vitro Alternative Methods for Developmental Neurotoxicity into International Hazard and Risk Assessment Strategies , 2007, Environmental health perspectives.

[23]  J. Parga,et al.  Mitochondrial ATP-sensitive potassium channels enhance angiotensin-induced oxidative damage and dopaminergic neuron degeneration. Relevance for aging-associated susceptibility to Parkinson’s disease , 2011, AGE.

[24]  D. Mastellos.  Complement emerges as a masterful regulator of CNS homeostasis, neural synaptic plasticity and cognitive function , 2014, Experimental Neurology.

[25]  L. Banaszak,et al.  5‐Hydroxydecanoate is metabolised in mitochondria and creates a rate‐limiting bottleneck for β‐oxidation of fatty acids , 2005, The Journal of physiology.

[26]  Miyoung Yang,et al.  Neurotoxicity of cancer chemotherapy☆ , 2013, Neural regeneration research.

[27]  L. Gollahon,et al.  Paclitaxel Induces Apoptosis in Breast Cancer Cells through Different Calcium—Regulating Mechanisms Depending on External Calcium Conditions , 2014, International journal of molecular sciences.

[28]  D. Weihrauch,et al.  Store-Operated Ca2+ Entry in Sensory Neurons: Functional Role and the Effect of Painful Nerve Injury , 2011, The Journal of Neuroscience.

[29]  M. Spira,et al.  Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: implications for the pathogenesis of paclitaxel-induced polyneuropathy , 2010, Acta Neuropathologica.

[30]  T. Galli,et al.  Biogenesis and transport of membrane domains-potential implications in brain pathologies. , 2014, Biochimie.

[31]  Gary J. Bennett,et al.  Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Evidence for mitochondrial dysfunction , 2006, Pain.

[32]  M. Saji,et al.  Paclitaxel-induced hyperalgesia modulates negative affective component of pain and NR1 receptor expression in the frontal cortex in rats , 2014, Neuroscience Research.

[33]  S. Jordt,et al.  Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation , 2007, Proceedings of the National Academy of Sciences.

[34]  Katsushi Yamada,et al.  Up‐regulation of matrix metalloproteinase‐3 in the dorsal root ganglion of rats with paclitaxel‐induced neuropathy , 2008, Cancer science.

[35]  Joshua A Harrill,et al.  Comparative sensitivity of human and rat neural cultures to chemical-induced inhibition of neurite outgrowth. , 2011, Toxicology and applied pharmacology.

[36]  C. Visovsky,et al.  Peripheral Neuropathy Caused by Paclitaxel and Docetaxel: An Evaluation and Comparison of Symptoms , 2013, Journal of the advanced practitioner in oncology.

[37]  G. Bennett,et al.  Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy , 2011, Experimental Neurology.

[38]  Daniela Gabriel,et al.  An imaging assay to analyze primary neurons for cellular neurotoxicity , 2010, Journal of Neuroscience Methods.

[39]  W. Gerwick,et al.  On the use of neuro-2a neuroblastoma cells versus intact neurons in primary culture for neurotoxicity studies. , 2005, Critical reviews in neurobiology.

[40]  Thomas Kuner,et al.  Synaptic plasticity in pathological pain , 2014, Trends in Neurosciences.

[41]  S. Feinstein,et al.  Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. , 2013, Neurotoxicology.

[42]  A. Ocean,et al.  Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. , 2011, Clinical breast cancer.